Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Inverse association between duration of use of acid-suppressive medications and fracture risk.

de Vries F.

Arch Intern Med. 2011 Jun 13;171(11):1044; author reply 1044. doi: 10.1001/archinternmed.2011.226. No abstract available.

PMID:
21670381
2.

Opportunities to decrease inappropriate uses of proton pump inhibitors: Comment on "Proton pump inhibitor use and the antifracture efficacy of alendronate".

Katz MH.

Arch Intern Med. 2011 Jun 13;171(11):1004-5. doi: 10.1001/archinternmed.2011.21. Epub 2011 Feb 14. No abstract available.

PMID:
21321289
3.

Proton pump inhibitor use and the antifracture efficacy of alendronate.

Abrahamsen B, Eiken P, Eastell R.

Arch Intern Med. 2011 Jun 13;171(11):998-1004. doi: 10.1001/archinternmed.2011.20. Epub 2011 Feb 14.

PMID:
21321287
4.

[Interactions of proton pump inhibitors with oral bisphosphonates and fracture risk].

Bartl R, von Tresckow E.

Dtsch Med Wochenschr. 2012 Apr;137(15):804-5. doi: 10.1055/s-0031-1298920. Epub 2012 Apr 10. German. No abstract available.

PMID:
22492419
5.

[Osteoporotic fracture in menopausal women: alendronate reduces the risk].

Bize R, Lamy O, Peytremann-Bridevaux I.

Rev Med Suisse. 2008 Dec 10;4(183):2703. French. No abstract available.

PMID:
19157286
6.

[New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].

Yamaguchi T, Sugimoto T.

Clin Calcium. 2009 Jan;19(1):38-43. doi: CliCa09013843. Review. Japanese.

PMID:
19122263
7.

A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.

Lee J, Youn K, Choi NK, Lee JH, Kang D, Song HJ, Park BJ.

J Gastroenterol. 2013 Sep;48(9):1016-22. doi: 10.1007/s00535-012-0722-9. Epub 2013 Jan 11.

PMID:
23307040
8.

Atypical subtrochanteric fractures after long-term bisphosphonate therapy.

CzerwiƄski E.

Endokrynol Pol. 2011 Jan-Feb;62(1):84-7. Review.

9.

Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study.

Chiu HF, Huang YW, Chang CC, Yang CY.

Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1131-6. doi: 10.1002/pds.2026.

PMID:
20872906
10.

Clinical concerns of alendronate use.

Rutkowski JL, Johnson DA, Smith DM.

J Oral Maxillofac Surg. 2007 Feb;65(2):363-4. No abstract available.

PMID:
17236956
11.

Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy.

Kajino Y, Kabata T, Watanabe K, Tsuchiya H.

J Orthop Sci. 2012 May;17(3):313-8. doi: 10.1007/s00776-011-0085-8. Epub 2011 May 21. No abstract available.

PMID:
21604044
12.
13.

Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm.

Moayyedi P, Cranney A.

Am J Gastroenterol. 2008 Oct;103(10):2428-31. doi: 10.1111/j.1572-0241.2008.02031.x. Review.

PMID:
18855852
14.

[Alendronate for treatment of osteoporoses].

Harada A.

Nihon Rinsho. 2009 May;67(5):943-7. Review. Japanese.

PMID:
19432114
15.

Proton pump inhibitors and fractures? Beware long-term use.

[No authors listed]

Prescrire Int. 2009 Oct;18(103):216. No abstract available.

PMID:
19885973
16.

Proton pump inhibitors and bone fractures?

Laine L.

Am J Gastroenterol. 2009 Mar;104 Suppl 2:S21-6. doi: 10.1038/ajg.2009.48. Review.

PMID:
19262543
17.

Evolving data about subtrochanteric fractures and bisphosphonates.

Shane E.

N Engl J Med. 2010 May 13;362(19):1825-7. doi: 10.1056/NEJMe1003064. Epub 2010 Mar 24. No abstract available.

PMID:
20335574
18.

The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.

Rietbrock S, Olson M, van Staa TP.

QJM. 2009 Jan;102(1):35-42. doi: 10.1093/qjmed/hcn130. Epub 2008 Oct 8.

PMID:
18842684
19.

Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis.

Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, Zhang X, He J.

Eur J Gastroenterol Hepatol. 2011 Sep;23(9):794-800. doi: 10.1097/MEG.0b013e328348a56a. Review.

PMID:
21701389
20.

[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].

Kishimoto H.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:365-8. Review. Japanese. No abstract available.

PMID:
18161133

Supplemental Content

Support Center